European Journal of Cancer, 165, 97-112 European Journal of Cancer, 165, pp. 97-112 Kennedy, O J, Kicinski, M, Valpione, S, Gandini, S, Suciu, S, Blank, C U, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, van Akkooi, A C J, Robert, C, Eggermont, A M M, Lorigan, P & Mandala, M 2022, ' Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 165, pp. 97-112 . https://doi.org/10.1016/j.ejca.2022.01.017